Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07876076
PHASE1

A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response

Sponsor: Adaxion Therapeutics

View on ClinicalTrials.gov

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ADX-001 in healthy adult participants

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Subcutaneous and Intravenous ADX-001 in Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

88

Start Date

2026-10-20

Completion Date

2028-12-14

Last Updated

2026-10-21

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

ADX-001

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

DRUG

ADX-001

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

DRUG

Placebo

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

Locations (1)

CMAX Clinical Research

Adelaide, South Australia, Australia